Key Takeaways KURA shares surged after FDA accepted its NDA for ziftomenib in NPM1-mutant acute myeloid leukemia. The NDA was backed by a phase II study showing significant remission rates and tolerable safety data. A $45M milestone from Kyowa Kirin was triggered upon NDA submission for ziftomenib in Q2 2025.Shares of Kura Oncology (KURA) have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, the FDA accepted the company’s new drug application (NDA) seeking full app ...